Evicenter
P&T meetings

BIM-IOL System

Open-angle glaucoma or ocular hypertension

Manufacturer
SpyGlass Pharma
Regulatory submission
NDA planned for 2028
Launch
Not announced
129 sources

Section 6 of 6

References

129 sources

  1. AbbVie Durysta prescribing information (2025) (opens in a new tab)
  2. AbbVie Lumigan prescribing information (2026) (opens in a new tab)
  3. Aboagye Yeboah et al. (2026) (opens in a new tab)
  4. AGIS Investigators (2000) (opens in a new tab)
  5. Ahmed et al. (2022) (opens in a new tab)
  6. Almidani et al. (2026) (opens in a new tab)
  7. Atik et al. (2022) (opens in a new tab)
  8. Bacharach et al. (2021) (opens in a new tab)
  9. Bartlett et al. (2020) (opens in a new tab)
  10. Baudouin et al. (2025) (opens in a new tab)
  11. Bhorade et al. (2021) (opens in a new tab)
  12. Bicket et al. (2021) (opens in a new tab)
  13. ClinicalTrials.gov NCT06120842 (opens in a new tab)
  14. ClinicalTrials.gov NCT07154797 (opens in a new tab)
  15. ClinicalTrials.gov NCT07154810 (opens in a new tab)
  16. ClinicalTrials.gov NCT07218783 (opens in a new tab)
  17. ClinicalTrials.gov NCT07218796 (opens in a new tab)
  18. ClinicalTrials.gov NCT07641296 (opens in a new tab)
  19. CMS Medicare Part B payment limit file (2026) (opens in a new tab)
  20. CMS Medicare Physician and Other Practitioners CPT 92083 data (2026) (opens in a new tab)
  21. CMS Medicare Physician and Other Practitioners CPT 92133 data (2026) (opens in a new tab)
  22. CMS MIPS Quality ID 141 specification (2026) (opens in a new tab)
  23. CMS MIPS Quality ID 191 specification (2026) (opens in a new tab)
  24. CMS MIPS Quality ID 389 specification (2026) (opens in a new tab)
  25. Craven et al. (2022) (opens in a new tab)
  26. Cvenkel and Kolko (2026) (opens in a new tab)
  27. Delaney-Gesing (2025) (opens in a new tab)
  28. Ehrlich et al. (2024) (opens in a new tab)
  29. Elam et al. (2016) (opens in a new tab)
  30. Fechtner et al. (2010) (opens in a new tab)
  31. Fiscella et al. (2009) (opens in a new tab)
  32. Friedman et al. (2007) (opens in a new tab)
  33. Garway-Heath et al. (2015) (opens in a new tab)
  34. Gazzard et al. (2019) (opens in a new tab)
  35. Gazzard et al. (2023) (opens in a new tab)
  36. GBD 2019 Blindness and Vision Impairment Collaborators (2021) (opens in a new tab)
  37. Gedde et al. (2022) (opens in a new tab)
  38. Gedde et al. (2026a) (opens in a new tab)
  39. Gedde et al. (2026b) (opens in a new tab)
  40. Glaukos iDose TR approval announcement (2023) (opens in a new tab)
  41. Glaukos iDose TR prescribing information (2026) (opens in a new tab)
  42. Gordon et al. (2002) (opens in a new tab)
  43. Gordon et al. (2024) (opens in a new tab)
  44. Gupta et al. (2012) (opens in a new tab)
  45. Gupta et al. (2016) (opens in a new tab)
  46. Halawa et al. (2022) (opens in a new tab)
  47. Hattenhauer et al. (1998) (opens in a new tab)
  48. Haymes et al. (2007) (opens in a new tab)
  49. Heijl et al. (2002) (opens in a new tab)
  50. Heijl et al. (2013) (opens in a new tab)
  51. Heijl et al. (2023) (opens in a new tab)
  52. Investing.com (2026) (opens in a new tab)
  53. Jarem (2025) (opens in a new tab)
  54. Jonas et al. (2017) (opens in a new tab)
  55. Kass et al. (2002) (opens in a new tab)
  56. Kass et al. (2021) (opens in a new tab)
  57. Kholdebarin et al. (2008) (opens in a new tab)
  58. Kim et al. (2026) (opens in a new tab)
  59. King et al. (2024) (opens in a new tab)
  60. Kolko et al. (2025) (opens in a new tab)
  61. Kruoch et al. (2025) (opens in a new tab)
  62. Lee et al. (2006) (opens in a new tab)
  63. Leske et al. (2003) (opens in a new tab)
  64. Leung et al. (2008) (opens in a new tab)
  65. Li et al. (2016) (opens in a new tab)
  66. Liao et al. (2026) (opens in a new tab)
  67. Luo et al. (2026) (opens in a new tab)
  68. Mader et al. (2023) (opens in a new tab)
  69. Malihi et al. (2014) (opens in a new tab)
  70. Mansberger et al. (2012) (opens in a new tab)
  71. McKean-Cowdin et al. (2008) (opens in a new tab)
  72. Medeiros et al. (2020) (opens in a new tab)
  73. Montesano et al. (2026) (opens in a new tab)
  74. Myers et al. (2025) (opens in a new tab)
  75. National Eye Institute (2026) (opens in a new tab)
  76. Newman-Casey et al. (2015) (opens in a new tab)
  77. Newman-Casey et al. (2020) (opens in a new tab)
  78. Newman-Casey et al. (2026) (opens in a new tab)
  79. NICE (2022) (opens in a new tab)
  80. Nordstrom et al. (2005) (opens in a new tab)
  81. Ophthalmology Times (2025) (opens in a new tab)
  82. Ophthalmology Times (2026) (opens in a new tab)
  83. Pazos et al. (2025) (opens in a new tab)
  84. Peters et al. (2013) (opens in a new tab)
  85. Peters et al. (2015) (opens in a new tab)
  86. Purola et al. (2023) (opens in a new tab)
  87. Quaranta et al. (2016) (opens in a new tab)
  88. Quintero et al. (2023) (opens in a new tab)
  89. Rasendran et al. (2022) (opens in a new tab)
  90. Rein et al. (2006) (opens in a new tab)
  91. Rein et al. (2022) (opens in a new tab)
  92. Samuelson et al. (2019) (opens in a new tab)
  93. Sarkisian et al. (2024a) (opens in a new tab)
  94. Sarkisian et al. (2024b) (opens in a new tab)
  95. Schoff et al. (2001) (opens in a new tab)
  96. Shah et al. (2022) (opens in a new tab)
  97. Shaikh et al. (2014) (opens in a new tab)
  98. Shan et al. (2024) (opens in a new tab)
  99. Shan et al. (2026) (opens in a new tab)
  100. Shih et al. (2021) (opens in a new tab)
  101. Silverstein et al. (2025) (opens in a new tab)
  102. Singh (2026) (opens in a new tab)
  103. Singh et al. (2024) (opens in a new tab)
  104. Sood et al. (2022) (opens in a new tab)
  105. SpyGlass Pharma 12-month Phase 1/2 results announcement (2026) (opens in a new tab)
  106. SpyGlass Pharma 36-month FIH and 3-month Phase I/II results announcement (2025) (opens in a new tab)
  107. SpyGlass Pharma CPT code announcement (2026) (opens in a new tab)
  108. SpyGlass Pharma first quarter 2026 results announcement (2026) (opens in a new tab)
  109. SpyGlass Pharma Form 10-K (2026) (opens in a new tab)
  110. SpyGlass Pharma Form 10-Q (2026) (opens in a new tab)
  111. SpyGlass Pharma fourth quarter and full year 2025 results announcement (2026) (opens in a new tab)
  112. SpyGlass Pharma IPO closing announcement (2026) (opens in a new tab)
  113. SpyGlass Pharma patent US12193972B2 (2025) (opens in a new tab)
  114. SpyGlass Pharma Phase III first randomization announcement (2026) (opens in a new tab)
  115. SpyGlass Pharma second quarter 2026 results announcement (2026) (opens in a new tab)
  116. Stein et al. (2012) (opens in a new tab)
  117. Stein et al. (2021) (opens in a new tab)
  118. Tan et al. (2026) (opens in a new tab)
  119. Terveen et al. (2022) (opens in a new tab)
  120. Tham et al. (2014) (opens in a new tab)
  121. Tsang et al. (2024) (opens in a new tab)
  122. Varma et al. (2011) (opens in a new tab)
  123. Varma et al. (2012) (opens in a new tab)
  124. Vision Loss Expert Group of the Global Burden of Disease Study (2024) (opens in a new tab)
  125. Wang et al. (2026) (opens in a new tab)
  126. Weinreb et al. (2014) (opens in a new tab)
  127. Yang et al. (2024) (opens in a new tab)
  128. Young (2024) (opens in a new tab)
  129. Zhang et al. (2015) (opens in a new tab)